A comparison of tocolysis with nifedipine and atosiban in preterm labor
Aim To compare the effectiveness and safety of nifedipine and atosiban in women with threatened preterm labor. Material and methods The study comprised 111 pregnant women presenting with threatened preterm labor between 30 and 34 weeks of gestation, who were assigned to receive tocolysis with either nifedipine (n=54) or atosiban (n=57). The effectiveness of tocolysis was determined by the duration of pregnancy prolongation (for 48 hours, 7 days, more than 14 days). The primary outcome was the rate of pregnancy prolongation for 48 hours. The safety of tocolytics was assessed by the rate of adverse events in mothers and the neonates. Results Tocolysis failed in eight women receiving nifedipine (14.8%) and two treated with atosiban (3.5%) (p <0.05), and labor occurred within the first 24 hours after beginning treatment. In 46 women receiving nifedipine (85.1%) and 55 treated with atosiban (96.5%) pregnancy was prolonged for more than 48 hours (p<0.05). Among them, all births occurred more than 7 days after the initiation of tocolysis. Two women of the atosiban group underwent a second complete treatment course. Full-term births occurred in 15 (27.8%) and 19 (33.3%) women in nifedipine and atosiban group, respectively (p> 0.05%). Mean duration of pregnancy prolongation after the tocolysis with atosiban was 9.2 days longer than after nifedipine (p <0.05). Women receiving nifedipine were more likely to have hot flushes, palpitations, dizziness and hypotension (p <0.01) requiring a dosage reduction and increasing the interval between doses in 14.8% of cases. Eight women in the nifedipine group did not complete the tocolysis protocol due to poor drug tolerance. Of them, in five women tocolysis was ineffective, and they progressed to delivery within 24 hours after admission. After exclusion from the analysis women failing to follow the treatment protocol, no differences were found in the effectiveness of tocolysis with nifedipine and atosiban. After adjusting the groups for multiple pregnancies, the rates of singleton pregnancy prolongation for 48 hours were 88.46% and 95.56% in the nifedipine and atosiban groups, respectively, and did not differ significantly (p> 0.05). However, the duration of pregnancy prolongation was significantly longer in women receiving atosiban (29.37 ± 14.95 days) than nifedipine (20.30 ± 11.95 days) (p <0.01). Conclusion The effectiveness of nifedipine and atosiban in pregnancy prolongation for 48 hours in threatened preterm labor is comparable. However, lower tolerability of nifedipine limits its applicability. Another advantage of atosiban is a longer period of pregnancy prolongation. Further studies are needed to clarify the effectiveness and safety of these drugs in the management of the threatened preterm labor in multiple pregnancies.Baev O.R., Vasilchenko O.N., Karapetyan A.O., Tetruashvili N.K., Khodzhaeva Z.S.
Keywords
preterm labor
tocolytics
atosiban
nifedipine
References
1. Савельева Г.М., Шалина Р.И., Курцер М.А., Клименко П.А., Сичинава Л.Г., Панина О.Б., Плеханова Е.Р., Выхристюк Ю.В., Лебедев Е.В. Преждевременные роды как важнейшая проблема современного акушерства. Акушерство и гинекология. 2012; 8-2: 4-10. [Savelyeva G.M., Shalina R.I., Kurtser M.A., Klimenko P.A., Sichinava L.G., Panina O.B., Plekhanova E.R., Vykhristyuk Yu.V., Lebedev E.V. Preterm birth as the most important problem of modern obstetrics. Akusherstvo i Ginekologiya/Obstetrics and Gynecology. 2012; 8-2: 4-10. (in Russian)]
2. Ходжаева З.С., Федотовская О.И., Холин А.М. Медикаментозная терапия угрожающих преждевременных родов. Акушерство и гинекология. 2013; 5: 17-22. [Khodzhaeva Z.S., Fedotovskaya O.I., Kholin A.M. Drug therapy for threatened premature birth. Akusherstvo i Ginekologiya/Obstetrics and Gynecology. 2013; 5: 17-22. (in Russian)]
3. Locatelli A., Consonni S., Ghidini A. Preterm labor: approach to decreasing complications of prematurity. Obstet. Gynecol. Clin. North Am. 2015; 42(2): 255-74.
4. Husslein P., Roura L., Dudenhausen J., Helmer H., Frydman R., Rizzo N. et al.; TREASURE study group. Clinical practice evaluation of atosiban in preterm labour management in six European countries. BJOG. 2006; 113(Suppl. 3):105-10.
5. Jørgensen J.S., Weile L.K., Lamont R.F. Preterm labor: current tocolytic options for the treatment of preterm labor. Expert Opin. Pharmacother. 2014; 15(5):585-8.
6. Crowther C.A., Brown J., McKinlay C.J., Middleton P. Magnesium sulphate for preventing preterm birth in threatened preterm labour. Cochrane Database Syst. Rev. 2014; (8): CD001060. doi: 10.1002/14651858.CD001060.pub2.
7. Neilson J.P., West H.M., Dowswell T. Betamimetics for inhibiting preterm labour. Cochrane Database Syst. Rev. 2014; (2): CD004352. doi: 10.1002/14651858.CD004352.pub3.
8. van Vliet E.O.G., Nijman T.A.J., Schuit E., Heida K.Y., Opmeer B.C., Kok M. et al. Nifedipine versus atosiban for threatened preterm birth (APOSTEL III): a multicentre, randomised controlled trial. Lancet. 2016; 387(10033): 2117-24. doi: 10.1016/S0140-6736(16)00548-1.
9. Nijman T.A.J., Goedhart M.M., Naaktgeboren C.N., de Haan T.R., Vijlbrief D.C., Mol B.W. et al. The effects of nifedipine and atosiban on perinatal brain injury: a secondary analysis of the APOSTEL III trial. Ultrasound Obstet. Gynecol. 2017; April 28. doi: 10.1002/uog.17512
10. de Heus R., Mulder E.J., Derks J.B., Visser G.H. The effects of the tocolytics atosiban and nifedipine on fetal movements, heart rate and blood flow. J. Matern. Fetal Neonatal Med. 2009; 22(6): 485-90.
11. Баев О.Р., Васильченко О.Н., Карапетян А.О., Тетруашвили Н.К., Ходжаева З.С. Сравнение токолиза гексопреналином и атозибаном. Медицинский совет. 2017; 2: 57-61. [Baev O.R., Vasilchenko O.N., Karapetyan A.O., Tetruashvili N.K., Khodzhaeva Z.S. Comparison of tocolysis with hexoprenaline and atosiban. Meditsinsky sovet. 2017; 2: 57-61. (in Russian)]
Received 08.12.2017
Accepted 22.12.2017
About the Authors
Baev Oleg Radomirovich, Dr.Med.Sci., Professor, Head of the Maternity Department, V.I. Kulakov NMRC AGP of the Ministry of Healthcare of the Russian Federation. Address: 117997, Russia, Moscow, Academician Oparin St., 4. E-mail: o_baev@oparina4.ruVasil’chenko Oksana Nikolaevna, Ph.D., Senior Researcher at the Maternity Department, V.I. Kulakov NMRC AGP of the Ministry of Healthcare of the Russian Federation. Address: 117997, Russia, Moscow, Academician Oparin St., 4. E-mail: o_vasilchenko@oparina4.ru
Karapetyan Anna Ovikovna, аспирант at the Maternity Department,V.I. Kulakov NMRC AGP of the Ministry of Healthcare of the Russian Federation.
Address: 117997, Russia, Moscow, Academician Oparin St., 4. a_karapetyan@oparina4.ru
Tetruashvili Nana Kartlosovna, Dr.Med.Sci., Head of the 2nd Obstetrics Department of Pregnancy Pathology, V.I. Kulakov NMRC AGP of the Ministry of Healthcare of the Russian Federation. Address: 117997, Russia, Moscow, Academician Oparin St., 4. E-mail: n_tetruashvili@oparina4.ru
Khodzhaeva Zul’fiya Sagdullaevna, Dr.Med.Sci., Professor, Head of the 1st Obstetrics Department of Pregnancy Pathology, V.I. Kulakov NMRC AGP of the Ministry of Healthcare of the Russian Federation. Address: 117997, Russia, Moscow, Academician Oparin St., 4. E-mail: z_khodzhaeva@oparina4.ru
For citations: Baev O.R., Vasilchenko O.N., Karapetyan A.O., Tetruashvili N.K., Khodzhaeva Z.S. A comparison of tocolysis with nifedipine or atosiban in preterm labor. Akusherstvo i Ginekologiya/Obstetrics and Gynecology. 2018; (5): 50-6. (in Russian)
https://dx.doi.org/10.18565/aig.2018.5.50-56
Similar Articles
